Search results
31 lip 2023 · Nitroglycerin is a vasodilatory drug used primarily to provide relief from anginal chest pain. It is currently FDA approved for the acute relief of an attack or acute prophylaxis of angina pectoris secondary to coronary artery disease.
7 lis 2017 · Nitroglycerin is the most frequently used drug to treat acute episodes of angina. It is usually given as a sublingual tablet, but is also available as a sublingual spray. Sublingual nitroglycerin or nitroglycerin oral spray can also be used prior to angina-inducing activities to prevent the occurrence of acute angina (8,104,105).
19 sie 2015 · This review discusses the efficacy and utility of short-acting nitroglycerin (sublingual spray and tablet) therapy for both preventing and aborting an acute angina attack, thereby leading to an improved quality of life. Keywords: angina, coronary artery disease, nitroglycerin spray, nitroglycerin sublingual tablets, optimal medical therapy.
9 lip 2022 · Nitroglycerin, a fast-acting vasodilator, is commonly used as a first-line agent for angina in the emergency department and to manage chest pain due to acute coronary syndromes. It is also a treatment option for other disease states such as acute heart failure, pulmonary edema, and aortic dissection ….
If no relief occurs, or if symptoms worsen 5 minutes after 1 dose of nitroglycerin has been taken, the patient should immediately call 9-1-1. 42 Patients at increased risk of ACS, such as those with known coronary artery disease (CAD), peripheral vascular disease, cerebral vascular disease, diabetes, or a 10-year Framingham risk of CAD of 20% ...
Tolerance towards antianginal and antiischemic effects does develop in a substantial number of patients with 24 hours, but this can be overridden by dose escalation and restoration of the therapeutic effectiveness of nitroglycerin.
1 mar 2023 · The high dose group reached their blood pressure faster on average (hazard ratio = 3.5, 95% CI: 1.2–10.1). 8/14 (57%) of patients in the high dose group reached their BP target within the first hour of treatment, compared to 6/27 (22%) in the low dose group.
